Abstract T P227: The Safety of Pioglitazone for Hematoma Resolution in IntraCerebral Hemorrhage (SHRINC) Trial: Safety Results
Background and Objectives: Peroxisome proliferator activated receptor-gamma agonists, such as pioglitazone (PIO) enhanced hematoma resolution and improved functional recovery in our animal model of intracerebral hemorrhage (ICH). We conducted a translational Phase II randomized, controlled clinical trial to determine the maximum tolerated dose (MTD) of PIO in patients with spontaneous ICH and to explore the rate of hematoma resolution and clinical outcome.
Methods: Patients with spontaneous ICH within 24 hours of symptom onset were randomly allocated 1:1 to placebo or PIO. Patients received escalating doses of PIO daily for three days, followed by a 30mg maintenance dose for the duration of treatment. Duration of treatment was when 75% of the ICH had resolved as determined by serial MRI or 10 weeks of treatment, whichever occurred first. The primary safety outcome was mortality at Day 14. Secondary measures of safety include any mortality, symptomatic cerebral edema, congestive heart failure, edema, hypoglycemia, anemia, and hepatotoxicity. Secondary measures of efficacy include hematoma resolution and clinical outcome. The MTD was determined using the Continual Reassessment Method.
Results: From March 2009 to April 2013, 84 patients (42 PIO, 42 control) were enrolled into 11 dose tiers, with a planned range from 0.1-2.0 mg/kg/d. Table 1 demonstrates preliminary baseline and clinical characteristics of patients by treatment group. Overall, 2/84 patients died within 2 weeks after ICH; however mortality rate never exceeded prespecified criteria. The study will be complete in October 2013 and the treatment team remains blinded to treatment allocation. Secondary outcomes by treatment group and the MTD of PIO will be reported.
Conclusions: We have completed the treatment phase of the SHRINC Trial. Long term follow-up is on-going. These results will provide the foundation for an efficacy trial evaluating PIO as a potential treatment for patients with spontaneous ICH.
Author Disclosures: N.R. Gonzales: Research Grant; Significant; SPOTRIAS P50-NS044227 from NINDS. N. Sangha: None. T. Kauffman: Research Grant; Significant; SPOTRIAS P50-NS044227. C. Cai: None. M. Sline: Research Grant; Significant; SPOTRIAS P50-NS044227. R. Pandurengan: Research Grant; Significant; SPOTRIAS P50-NS044227. H. Peng: None. L. Sosa: None. R. Bowry: None. M.P. Prieto: None. M. Hossain: None. J. Kawano-Castillo: None. E.E. Choi: None. G.D. Villamar: None. K. Ofori: None. L.A. Aramburo-Maldonado: None. L. Shen: None. I. Acosta: None. M. Kasam: None. N. Harun: None. A.D. Barreto: None. T. Wu: None. A. Sarraj: None. S.I. Savitz: None. G. Lopez: None. N.L. Ifejika: Research Grant; Significant; SPOTRIAS P50-NS044227. M.H. Rahbar: Research Grant; Significant; SPOTRIAS P50-NS044227. X. Zhao: None. J. Aronowski: None. J.C. Grotta: Research Grant; Significant; SPOTRIAS P50-NS044227.
This research has received full or partial funding support from the American Heart Association, National Center.
- © 2014 by American Heart Association, Inc.